ANACOR TO PRESENT AT COWEN AND COMPANY HEALTH CARE CONFERENCE

Palo Alto, Calif. - March 10, 2009 - Anacor Pharmaceuticals announced today that David Perry, Chief Executive Officer, will provide a company overview at the Cowen and Company 29th Annual Health Care Conference at 2:00 p.m. ET on Monday, March 16, 2009 in Boston.

About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. In addition, the Company is developing systemic antiviral and antibacterial therapeutics under a research and development agreement with GlaxoSmithKline. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough Corporation under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. For more information visit www.anacor.com.

Contact:
Anne Bowdidge
650-543-7575